美托洛尔联合螺内酯治疗扩张型心肌病心力衰竭的临床分析

Clinical Analysis of Metoprolol Combined Spirolactone in the Treatment of Dilated Cardiomyopathy-chronic Heart Failure

目的:探讨美托洛尔联合螺内酯治疗扩张型心肌并心力衰竭的临床效果。方法:抽选2013年1月~2014年2月在某院就诊并接收治疗的扩张型心肌病心力衰竭患者105例患者,结合患者入院时间先后分为观察组(52例)和对照组(53例),进行研究分析。结果:观察组治疗有效率90.4%,对照组71.7%,差异显著(P<0.05)。观察组患者治疗后LVEDD、LVESD相较对照组存在明显差异(P<0.05),而LVEF对比无显著性差异(P>0.05);两组患者不良反应发生率对比差异无显著性(P>0.05)。结论:美托洛尔联合螺内酯治疗扩张型心肌病心力衰竭患者疗效显著,更加有效的改善患者心功能指标,值得临床推广。

Objective：To investigate the clinical effect of metoprolol combined spirolactone in the treatment of dilated cardiomyopathy-chronic heart failure.Methods：105cases of patients with dilated cardiomyopathy-chronic heart failure treated in a hospital from January 2013 to February 2014 were selected and divided into observation group（52cases）and control group（53cases）according to the admission time,then analyzed the treatment effect.Results：The treatment effective rate of observation group was 90.4%,and that of control group was 71.7%,which the difference was significant（P〈0.05）.After treatment,There was significant difference in LVEDD and LVESD between the two groups（P〈 0.05）,and there was no significant difference in LVEF（P〉0.05）.There was was no significant difference in the incidence of adverse reactions of two groups（P〉0.05）.Conclusion：Metoprolol combined spirolactone in the treatment of dilated cardiomyopathy-chronic heart failure has significant effect,which can effectively improve cardiac function of patients,and is worthy of clinical promotion.